ABOUT KAMARI

Advancing skin health through the development of novel therapies for rare dermatologic diseases & itch conditions

Kamari Pharma was founded in 2018 to develop innovative treatments for unmet needs and rare diseases in dermatology. We are developing proprietary small molecules, selective TRPV3 inhibitors for regulation of skin physiology and pathology.

We are aiming to treat conditions of the skin with no current treatments by targeting the root cause of Ca+2 dysregulation.

TRPV3 was established as a target for drug development and showed involvement in various skin disorders including Olmsted Syndrome, Keratodermas, Pruritus, Ichthyosis, Atopic Dermatitis,  and others.

The Company is comprised of individuals with vast experience in drug discovery and dermatology pharmaceutical development in the biotech industry, as well as clinical advisors who are world-class key opinion leaders in related scientific areas. Our team includes a strong board of directors with a proven track record of success in advancing therapies to treat both rare diseases and dermatologic diseases and conditions.